Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: microneedling with topical crisaborole.
- Who it may be relevant to
- Registry conditions: Vitiligo. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. A Prospective Controlled Trial.
Overview
The goal of this clinical trial is to learn if topical crisaborole ointment works to treat vitiligo. It will also learn about the safety of the drug. The main questions it aims to answer are: Can the drug cause repigmentation of vitiligo lesions when used as topical form after microneedling? What medical problems do participants have when the drug used? Participants will: Visit the clinic once every 2 weeks to have the microneedling sessions for 3 months. and also they will have narrow band UVB sessions two times per week. Record any side effect they have during or after the sessions.
Interventions
- Procedure microneedling with topical crisaborole
From each patient 3 patches will be selected The first will have microneedling and topical crisaborole and NB UVB sessions The second will have microneedling and NB UVB sessions The third will be exposed only to NB UVB sessions The microneedling sessions will be every 2 weeks for 6 sessions
Primary outcome measures
- Repigmentation of vitiligo lesions [Time frame: 3 months from the start of treatment]
Eligibility criteria
Inclusion criteria
- Patients suffer from non-segmental stable vitiligo.
- Patients who will accept to be included in the study and will sign a written consent.
Exclusion criteria
- Patients with history of koebnerization or any sign of disease activity.
- Patients with keloid tendency.
- Patients with active infection.
- Pregnant or lactating woman.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07088276 · 36264MS976/6/25